Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2006

View Archived Issues

Crucell looks back on 2005 achievements

AstraZeneca updates Q4 accomplishments

Neuroprotective potential of the HCT PAN-811

Cytogen and Savient sign letter of intent for Soltamox U.S. rights

Orphan drug designation for Ultratrace MIBG

Immune Response to focus on NeuroVax and IR-103

Targeting FXR for hyperglycemia and hyperlipidemia in diabetes

Avexa signs license agreement with MNLpharma for HIV integrase inhibitors

Neose Technologies receives milestone from Novo Nordisk

Nymox updates Alzheimer's programs

Zelos completes enrollment in two phase II studies of Ostabolin-C

Insert submits IND for phase I trials of IT-101

Novartis Ophthalmics to copromote Retisert with Bausch & Lomb

FDA Committee recommends ADHD drug medication guide

Dosing completed in phase IIb study of VLTS-934 in PAD

Recruitment suspended in AVANT trial for safety data review

Isis looks ahead to anticipated milestones of 2006

Progressive weight loss observed in pramlintide dose-ranging study

New MCD inhibitor could be beneficial for ischemic heart disease

Accentia Biopharmaceuticals to launch new combination pain product

New selective nonpeptide CCR8 agonist presented

Recent patents disclose new antiinfective agents

Novel treatments for gastrointestinal disorders described in recent patents

Recent Pfizer patent discloses therapeutic agents for alopecia and acne

Propofol under clinical investigation for the treatment of refractory status epilepticus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.